Core Viewpoint - ST诺泰 and six executives were penalized a total of 76.2 million yuan due to false records in annual reports and public issuance documents [1][2][3] Group 1: Penalties and Violations - ST诺泰 was fined 47.4 million yuan, while its actual controller and former vice chairman, Zhao Dezhong, was fined 13 million yuan [2] - Other executives received varying fines: Zhao Deyi (500,000 yuan), Jin Fuqiang (330,000 yuan), Tong Ziquan and Gu Haitao (300,000 yuan each), and Xu Donghai (150,000 yuan) [2] - The total penalty amount sums up to 76.2 million yuan [3] Group 2: Financial Misrepresentation - In December 2021, ST诺泰 recognized 30 million yuan in business income from a technology transfer to Zhejiang Huabei, which lacked the financial capability to pay [1] - This transaction led to an inflated operating income of 30 million yuan and an inflated total profit of 25.9516 million yuan, accounting for 20.64% of the reported profit for that period [1] Group 3: Company Operations and Future Actions - ST诺泰 stated that its production and operational activities are currently proceeding normally and in an orderly manner [3] - The company plans to take this incident as a lesson, actively implement rectifications, and enhance internal control processes [3] - ST诺泰 focuses on peptide drugs and small molecule chemical drugs, with a strategic layout in oligonucleotide business, combining independent research and customized research and production [3] Group 4: Recent Financial Performance - For the first three quarters of 2025, ST诺泰 reported an operating income of 1.527 billion yuan, representing a year-on-year growth of 21.95% [3] - The net profit attributable to shareholders was 445 million yuan, showing a year-on-year increase of 26.92% [3]
ST诺泰年报及发行文件虚假记载被罚7620万元